Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
April 12, 2024 16:01 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful...
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
April 01, 2024 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
March 25, 2024 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
March 19, 2024 21:49 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
March 19, 2024 16:01 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful...
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
March 14, 2024 17:23 ET
|
Aquestive Therapeutics, Inc.
Anaphylm meets all predefined primary and secondary pharmacokinetic endpointsAnaphylm time to maximum concentration (Tmax) is consistently faster than autoinjectorsAnaphylm exposure levels (AUC) are...
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 05, 2024 17:05 ET
|
Aquestive Therapeutics, Inc.
Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 millionReaffirms expected release of topline pivotal clinical data for Anaphylm™ (epinephrine) Sublingual...
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
February 21, 2024 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful...
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting
February 15, 2024 08:00 ET
|
Aquestive Therapeutics, Inc.
The clinical trial data show that epinephrine delivered via orally administered Anaphylm™ (epinephrine) Sublingual Film is comparable to epinephrine delivered via autoinjector or manual intramuscular...
Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference
January 30, 2024 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through...